Predictive value of genetically engineered endogenous mouse models in preclinical therapeutic studies

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies with an alarming resistance to both chemotherapeutics and targeted therapy approaches. Genetically engineered mouse models (GEMM) of PDAC reflect molecularly and pathophysiologically the carcinogenesis and cancer progression observed in humans, thus being excellent tools for preclinical evaluation of new therapies. To successfully predict and characterize the effect of chemotherapies and targeted approaches in PDAC, we use a complex and highly aggressive GEMM of endogenous PDAC, Ptf1a +/Cre Kras +/LSL-G12D p53Lox/Lox (CKP) mice.…